Eli Lilly
NYSE:LLYPharmaIndianapolis, IN, United States · Est. 1875 · 43,000 employees
Global healthcare leader creating medicines that make life better.
59
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
58
Indications↗
Distinct diseases across all programs
2,368
Clinical Trials↗
All sponsored trials (all statuses)
52
Orange Book Patents
Across 9 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
59 drugs in development
Approved2
Phase 36
Phase 220
Phase 134
Preclinical6
By Therapeutic Area
top 6
Oncology
2436%
Metabolic & Endocrine
812%
Neurology
812%
Immunology
69%
Musculoskeletal
46%
Nephrology
23%
R&D Momentum
100/100
Pipeline Velocity
88/100
Trial Completion Rate
92/100
Pipeline Concentration
20/100
Pipeline Freshness
74/100
Strategic Signals
- ↗Active in Gastroenterology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Nov 4, 2026
Completed
A Single- and Multiple-Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of LY3867070 in Healthy Participants
Nov 4, 2026
Recruiting
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Clazakizumab in Reducing hsCRP in Adults With Elevated hsCRP and Established ASCVD or at Increased Risk for ASCVD Events
Nov 4, 2026
Recruiting
Long-Term Real-World Comparative Effectiveness of Donanemab Plus Usual Care Versus Usual Care Alone in US Patients With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-REAL US)
Nov 4, 2026
Recruiting
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm Study to Investigate the Efficacy and Safety of Adjunctive Treatment With Brenipatide in Delaying Time to Relapse Compared With Placebo in Adult Participants With Major Depressive Disorder (RENEW-MDD- 2)
Oct 30, 2026
Recruiting
A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3954068 in Patients With Early Symptomatic Alzheimer's Disease
Oct 29, 2026
Recruiting
An Annual Dosing Study of Donanemab in Participants Who Completed Donanemab Study AACM
Oct 29, 2026
Recruiting
A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants With Severe Alopecia Areata
Oct 28, 2026
Active, not recruiting
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab/ LY3650150 in Adult Participants With Perennial Allergic Rhinitis
Details
Company Info
Company Overview
$750.0B
Mkt Cap
$34.1B
Revenue
$3.6B
Cash
CEODavid Ricks
Founded1875
Employees43,000
HQIndianapolis, IN, United States
ExchangeNYSE:LLY
Websitelilly.com
LinkedInCompany Page
Therapeutic Focus
Metabolic & EndocrineOncologyImmunologyCardiovascularOtherDermatologyNephrologyNeurologyInfectious DiseaseMusculoskeletalHematologyPsychiatryRare DiseaseGastroenterologyOphthalmology
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cardiovascular(1 drug)
—
—
—
1
—
Cardiovascular(1 drug)
Dermatology(1 drug)
—
—
—
1
—
Dermatology(1 drug)
Gastroenterology(1 drug)
—
—
—
—
1
Gastroenterology(1 drug)
Immunology(6 drugs)
1
2
2
1
1
Immunology(6 drugs)
Metabolic & Endocrine(8 drugs)
2
2
3
2
1
Metabolic & Endocrine(8 drugs)
Musculoskeletal(4 drugs)
—
—
4
—
—
Musculoskeletal(4 drugs)
Nephrology(2 drugs)
—
2
—
—
—
Nephrology(2 drugs)
Neurology(8 drugs)
2
2
3
1
—
Neurology(8 drugs)
Oncology(24 drugs)
1
18
6
1
—
Oncology(24 drugs)
Unknown / Other(11 drugs)
—
11
2
—
1
Unknown / Other(11 drugs)
Regulatory
Regulatory Timeline
202511 events
FDADec 2
Jaypirca — JAYPIRCA
Application NDA216059
FDANov 20
Retevmo — RETEVMO
Application NDA213246
FDANov 20
Retevmo — RETEVMO
Application NDA213246
FDANov 20
Retevmo — RETEVMO
Application NDA218160
FDANov 20
Retevmo — RETEVMO
Application NDA218160
FDAOct 28
EBGLYSS — EBGLYSS
Application BLA761306
FDAOct 23
Omvoh — OMVOH
Application BLA761279
FDASep 25
Inluriyo — INLURIYO
Application NDA218881 (NDA)
FDAJul 9
Genotropin — GENOTROPIN PRESERVATIVE FREE, GENOTROPIN
Application BLA020280
FDAJul 1
Kisunla — KISUNLA
Application BLA761248
FDAMay 28
Glargine — SOLIQUA 100/33
Application BLA208673
20269 events
FDAJul 14
Retevmo — RETEVMO
Application NDA213246
FDAJul 14
Retevmo — RETEVMO
Application NDA218160
FDAJul 13
Verzenio — VERZENIO
Application NDA208716
FDAJun 30
Olumiant — OLUMIANT
Application NDA207924
FDAJun 9
EBGLYSS — EBGLYSS
Application BLA761306
FDAJun 5
Emgality — EMGALITY
Application BLA761063
FDAApr 1
Foundayo — FOUNDAYO
Application NDA220934 (NDA)
FDAMar 12
Glargine — SOLIQUA 100/33
Application BLA208673
FDAJan 26
Folvite — QUIOFIC
Application NDA216395 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)